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RESUMO 
O carcinoma da próstata (CaP) é, mundialmente, uma das neoplasias 
malignas com maior incidência e prevalência no sexo masculino, constituindo 
uma das principais causas de morbilidade e mortalidade oncológica. O 
conhecimento limitado da sua biologia compromete o desenvolvimento de novos 
marcadores de diagnóstico e prognóstico, capazes de melhorar a monitorização 
e terapêutica desta neoplasia. Atualmente é reconhecido que a desregulação 
epigenética desempenha um papel fundamental na carcinogénese prostática. A 
expressão anormal de enzimas modificadoras de histonas, nomeadamente das 
metiltransferases (MTHs) e das desmetilases (DMHs), tem sido associada ao 
desenvolvimento do CaP, bem como as modificações pós-transducionais (MPTs) 
das histonas estabelecidas por estas enzinas. Contudo, a importância da 
desregulação da atividade/expressão de alguns membros das MTHs e DMHs 
permanece ainda por esclarecer.  
Num estudo prévio usando uma amostragem reduzida, verificámos que a 
MTH PRMT6 estava significativamente sobrexpressa no CaP comparativamente 
aos tecidos prostáticos normais (TPNs), tendo igualmente demonstrado uma boa 
capacidade na distinção entre TPNs e CaP. Tendo como base estes resultados 
preliminares, os principais objectivos desta dissertação de mestrado foram 
validar a sobrexpressão da PRMT6 em CaP numa série alargada, bem como 
investigar o seu putativo papel oncogénico na carcinogénese prostática, 
recorrendo a modelos in vitro. 
A sobrexpressão da PRMT6 foi observada quer ao nível do transcrito quer 
ao nível da sua expressão proteica tanto nos CaP como nos PIN.  
Os estudos in vitro na linha celular PC-3 silenciada (PC-3 Sh-PRMT6) 
demonstraram um aumento significativo das células em apoptose, assim como a 
diminuição da viabilidade celular e da capacidade migratória e invasiva. 
Contrariamente, na linha celular LNCaP o silenciamento da PRMT6 não atenuou o 
fenótipo maligno, provavelmente, devido ao seu status de expressão de 
receptores de androgénios. Adicionalmente, a nível molecular a linha celular PC-3 
Sh-PRMT6 apresentou diminuição global na expressão da marca H3R2me2a. 
Contudo, não se verificou alteração nos padrões de expressão da marca 
H3K4me3, embora os níveis de expressão das enzimas catalisadoras desta MPT 
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(complexo MLL e a SMYD3) tenham aumentado significativamente. O 
silenciamento da PRMT6 associou-se significativamente com o aumento dos 
níveis de transcrito do p21, p27 e CD44, bem como com a diminuição da 
expressão da MMP-9. Relativamente às vias de sinalização celular, o 
silenciamento da PRMT6 conduziu a uma redução da via PI3K/AKT/mTOR e a um 
aumento da via dos receptores de androgénios, sugerindo um papel oncogénico 
desta enzima. 
De modo a confirmar que as alterações observadas são uma consequência 
direta da atividade da PRMT6 serão necessários estudos complementares. De 
igual modo, serão efetuados ensaios adicionais in vitro para esclarecer a 
utilidade terapêutica da re-expressão dos receptores de androgénios na linha 
celular PC-3. De facto, a restauração da expressão do AR em células PC-3 Sh-
PRMT6, pode ser clinicamente relevante, uma vez que pode voltar a sensibilizar 
células neoplásicas andrógeno-insensitive a ADT. 
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SUMMARY 
Prostate cancer (PCa) is one of the most incident and prevalent cancers in 
men worldwide, and a leading cause of cancer-related morbidity and mortality. 
The limited knowledge about its biology hinders the development of new 
diagnostic and prognostic markers, able to improve management and therapeutic 
of this malignancy. Epigenetics plays an important role in prostate carcinogenesis 
and in fact, abnormal expression of histone modifier enzymes, such as histone 
methyltransferases (HMTs) and demethylases (HDMs), and its chromatin 
modifications are related to PCa. Notwithstanding, the specific role of 
deregulated activity/expression of several members of both HMTs and HDMs is 
still poorly understood.  
Previously, we have found in a small number of clinical samples that 
PRMT6 was overexpressed in PCa compared to normal prostate tissue samples 
(NPTs) and demonstrated a promising capacity to distinguish NPTs from PCa. 
Based on these previous results, the main goals of this work were to validate the 
overexpression of PRMT6 in PCa and further explore its putative oncogenic role in 
prostate carcinogenesis, using in vitro models. 
Using a large series of prostatic samples we found that PRMT6 was 
overexpressed in PCa, at both transcript and protein level. Intriguingly, PIN 
lesions displayed significantly higher PRMT6 expression levels, compared to PCa. 
Furthermore, PRMT6 mRNA levels are able to discriminate cancerous from non-
cancerous prostate tissues. 
Contrarily to LNCaP, stable PRMT6 knockdown in PC-3, attenuated the 
malignant phenotype, in which the increased apoptosis as well as the decreased 
viability levels, migration and invasion ability was observed.  
Moreover, at molecular level, PRMT6 silencing was associated with 
decreased H3R2me2a levels and increased MLL complex and SMYD3 expression, 
although no global H3K4me3 levels were found.  
The silencing of PRMT6 significantly associated with increased expression 
levels of p21, p27 and CD44, as well as decreased expression of MMP-9. 
Regarding signaling pathways, PRMT6 knockdown related with a reduction of the 
PI3K / AKT / mTOR pathway and an increase in AR, supporting an oncogenic role 
for this enzyme. 
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Nevertheless, to confirm the observed alterations as a direct consequence 
of PRMT6 activity further experiments are needed. Similarly, additional in vitro 
studies should be performed to elucidate the specific therapeutic utility of AR re-
expression in PC-3 cell line. Indeed, restoration of AR expression in Sh-PRMT6 PC-
3 cells, might be of clinical relevance as it may re-sensitize androgen-insensitive 
neoplastic cells to ADT. 
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1 PROSTATE 
1.1 Prostate Anatomy and Histology  
Herophilus of Alexandria first used the term “prostate” in 335 b.C., 
referring the organ localized in front of human urinary bladder [1]. The human 
prostate is a pear-shaped exocrine gland and as part of the male reproductive 
system plays an essential role in secretion of important components of the 
seminal fluid, as well as in ejaculation [2-4] .The prostate base is located at the 
bladder neck and its apex at the urogenital diaphragm [5, 6]. In normal adults, 
prostate weights up to 20 g and measures approximately 25cm3 [2, 4].  
In 1981, McNeal proposed the most widely accepted model of prostate 
anatomic organization (Figure 1) [7]. According to McNeal, prostate is divided in 
four basic regions: peripheral, central and transition zones and anterior 
fibromuscular stroma (AFMS) (Figure 1). The peripheral zone constitutes about 
70% of the glandular prostate and is located at the posterior and lateral sides of 
the gland. The central zone represents about 25% of the glandular tissue, it is 
posterior to the urethra and surrounds the two ejaculatory ducts. The transitional 
zone encases the prostatic urethra and accounts for 5% of glandular elements. 
AFMS forms the entire anterior surface of the prostate as a thick non-glandular 
layer, which extends from the bladder neck to the striated sphincter [6-8]. 
Histologically, acini and ducts compose the prostate´s glandular 
component. The ducts are subdivided into large (primary, major or excretory) and 
peripheral (secondary or minor). Typically, both acini and ducts contain two 
layers of epithelial cells: secretory cells and basal cells [2]. Moreover, 
neuroendocrine cells are rare in normal prostate epithelium [4]. 
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1.2 Non-malignant Disorders of Prostate 
Prostate has higher frequency and extent of non-malignant lesions than 
other organs [9], being more common in aged men [10]. Benign prostatic 
hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and proliferative 
inflammatory atrophy (PIA) are among the most common pre-malignant lesions of 
this gland. 
BPH is a chronic disease affecting more than half of the male population 
over 50 years old [10]. Coexistence of BPH and prostate cancer (PCa) was first 
described in 1957 in a necropsy study, in which BPH was identified in 80% and 
45% of cadavers with and without PCa, respectively [11]. Although BHP and PCa 
share several common pathophysiological mechanisms they exhibit important 
differences in terms of histology and localization. However, it is still not clear if 
BHP represents the first step in the pathway to PCa [11].  
Figure 1: Anterior oblique view of the prostate and urethra. The prostate is 
divided into four zones: central zone (CZ), transition zone (TZ), peripheral zone 
(PZ) and anterior fibromuscular stroma (AFS). Adapted from [8]. 
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In 1987, PIN lesions were first described by Bostwick and Brawer [12] 
being those lesion classified into low-grade (LGPIN) and high-grade (HGPIN). 
Although, only HGPIN is widely accepted as a precursor lesion of PCa.  
This lesion is characterized by progressive phenotype and genotype 
abnormalities that are intermediate between benign prostatic epithelium and 
cancer [13, 14]. The frequency of HGPIN in prostate biopsies averages 9% and the 
severity and frequency of these lesions at postmortem examination are greatly 
increased in individuals with cancerous prostates comparing with noncancerous 
prostates [13, 15]. In addition to the similar cytologic features, HGPIN and PCa 
share genetic and molecular markers as well as other characteristics, such 
increased incidence with age and preferential occurrence at prostatic peripheral 
zone. These characteristics, combined with the fact that HGPIN precedes the 
onset of PCa in about 10 years, suggest that HGPIN represents an intermediate 
stage between benign epithelium and the invasive malignant carcinoma. Thus, 
HGPIN might have a clinical significance as a tool to identify patients at risk of 
malignancy [14]. 
PIA has been also suggested as a precursor of PCa and HGPIN. This lesion 
is described as a hyperproliferative entity associated with chronic inflammation 
and with distinct morphological appearance recognized as prostatic atrophy [16]. 
The hypothesis that PIA could be a potential precursor of other prostate lesions 
stems from the fact that this lesion usually occurs in the prostate peripheral zone 
and shares some molecular features found both in PIN and PCa [13]. Despite 
those findings, evidence to date is inconclusive as to whether PIA is a precursor 
of HGPIN and PCa [13]. 
1.3 Prostate Cancer 
Adenocarcinoma of the prostate accounts for 95% of all malignancies in 
this gland [3]. PCa is an age-related disease, being very heterogeneous in terms 
of pathologic, biologic and clinical behavior, ranging from clinical indolent to 
highly aggressive neoplasia [6, 17]. This malignancy is multicentric and has no 
specific symptoms, which leads to a late diagnosis and compromises not only 
prognosis but also the attempts to develop target therapies [6].  
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Histologically, PCa is characterized by loss of both basal cell layer and 
membrane. Remarkably, in HGPIN this cell layer is fragmented and in BPH, both 
are intact. This finding suggests the existence of a sequential pathway in PCa 
development (Figure 2) although the underlying mechanisms that lead to PCa still 
not fully understood [18]. 
  
1.3.1 Epidemiology of Prostate Cancer 
Current epidemiological data indicates this neoplasm as a major health 
concern. In 2012, 1,111,689 new cases were diagnosed worldwide 
(approximately 15% of total newly diagnosed cancers in men), making it the 
second most commonly diagnosed cancer in male population, only outshined by 
lung cancer [19].  
PCa incidence rates are very heterogeneous around globe, being estimated 
more than a 25-fold variation. In fact, about 70% of new diagnosed cases in 2012 
occurred in more developed countries, being the higher incidences reported in 
United States, Australia and Nordic countries, whereas lower incidence rates are 
observed in Asia [19]. (Figure 3) 
 
 
 
 
Figure 2: Progression pathway for prostate cancer. Adapted from [3]. 
Figure 3: Estimated age-standardized incidence rates of PCa per 100,000, 
worldwide. Adapted from [19]. 
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Regarding mortality, a slight decrease in mortality rates were observed 
among developed countries. However, the mortality rates are much less variable 
than incidence, accounting only a 10-fold variation worldwide [19]. 
Restricting this analysis to Europe, PCa arises as the most incident cancer 
and the third cause of cancer-related mortality. In Portugal, PCa is also the most 
frequent cancer among men, with 6,622 newly diagnosed cases in 2012 (23,3% of 
overall cancers) and the third leading cause of cancer related death (11,1% of 
overall cancer related deaths) [19]. (Figure 4) 
 
 
1.3.2 Risk Factors 
Although the etiology and pathogenesis of PCa is quite complex, there are 
three well-established and widely accepted risk factors [20]. 
 
Race: PCa remains as one of the most singular cancers regarding 
geographical distribution. Globally, African American men have a higher risk to 
develop PCa and tend to be diagnosed at younger ages and with more advanced 
stage, which reflects the higher mortality rates in this population, comparing to 
European American men [21].  
Asian men have the lowest incidence rates of PCa but Asian males living in 
the United States exhibit a higher risk to develop this malignancy [22]. The exact 
and scientific explanation for these disparities is still unknown, however genetic, 
Figure 4: Incidence and mortality of different cancers in Europe and Portugal. Adapted from [19]. 
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environment, social or cultural factors also in addition to differences in the 
decision-making practice, access to medical care and preferred diagnostic tools, 
might play an important role in this unequal distribution of PCa around the globe 
[23, 24].  
 
Family history: Men´s probability of developing PCa is higher within a 
family history of the disease is present. Currently, it is estimated that 10-15% of 
all PCa are associated with familial cases [23]. In fact, men with first-degree 
relatives (father or brother) harboring PCa have more than double of risk to 
develop this disease. Additionally, the number of members affected and the 
early-onset of disease increase even more the risk of developing PCa. This might 
suggest an involvement of a genetic predisposition, although other features like 
exposure to the same environmental factors should also be considered [22, 23]. 
 
Age: As a consequence of a clinical latent course, age is the most 
important recognized risk factor for PCa incidence [17, 23]. Malignancies of 
prostate gland are more frequent in older men, with a median age at diagnosis of 
67 years. Approximately 85% of PCa cases are diagnosed after the age of 65 
years old and in men older than 90 years old, the incidence is higher than 90% 
[22, 23, 25].   
 
1.3.3 Current Guidelines for Prostate Cancer Diagnosis 
Diagnosis of PCa is quite hampered by indolent behavior of this 
malignancy. Thus, improvement of detection tools to diagnose the disease when 
it is organ confined is the best approach. Serum concentration of prostate-
specific antigen (PSA) and digital rectal examination (DRE) are generally used as a 
standard methodology to PCa screening and management [26]. DRE is capable to 
detect about 18% of all PCa, regardless of the PSA level [27].  
PSA is a glycoprotein with protease activity produced by epithelial cells of 
prostate gland, which is secreted in the glands lumina and is released into the 
bloodstream in increased quantities when disruption of normal prostatic 
membrane structures occurs. This phenomenon arises not only in malignant 
lesions, but also in the context of inflammation, hyperplasia and urologic 
manipulation. Therefore, PSA is prostate specific, but not PCa specific. 
Additionally, PSA not only lacks sensitivity to detect an important number of PCa 
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cases, especially at early stages, but also increases the overdiagnosis and 
overtreatment of indolent tumors, demonstrated a limited value as a screening 
test [28]. 
According with international guidelines, men with inconclusive or 
suspicious DRE result and/or PSA value equal or higher than 4.0 ng/mL, must be 
considered for transrectal ultrasound (TRUS)-guided biopsy. Additionally, when a 
patient is considered for biopsy, clinicians should take into account factors such 
patients’ age, possible comorbidities and therapeutic consequences. It should be 
taken in consideration that both PSA and DRE are fallible, once there are PCa 
cases with normal DRE and/or lower levels of PSA [29-31].  
Nevertheless, the combination of PSA test and DRE allowed for an 
important decrease in the number of cases with advanced disease at the 
diagnosis (about 70-80% of PCa are organ confined), which increases the disease-
free survival [4].  
 
1.3.4 Prostate Cancer Grading System: Gleason Score 
The Gleason score (GS) is the widespread accepted system for grading PCa. 
This system is based on the histological evaluation of glandular epithelial 
architecture pattern, excluding cytological aspects from the analysis. Given the 
PCa heterogeneity, it classifies the two most prevalent patterns in a 1 to 5 scale, 
with a decreasing grade of differentiation (1- Most differentiated; 5- Least 
differentiated) (Figure 5). Thus, the GS consists in the sum of the classification of 
the two most common patterns, ranging from 2 (1+1) to 10 (5+5) [4, 32]. 
In 2005, International Society of Urological Pathology (ISUP) published the 
last update of this classification, considering that GS of a prostate biopsy should 
include the Gleason grade of the prevalent carcinoma pattern and the highest 
grade, independently of its extent. The predominant pattern has a crucial role in 
prognostic evaluation, specifically in GS = 7 lesions, because the predominance of 
pattern 4 (Gleason 4+3) carries more than a 3-fold higher risk of PCa mortality 
than Gleason pattern 3+4 [33, 34].  
Since 1966, when Donald Gleason firstly proposed this grading system, it 
is along with pathologic stage, a powerful tool for PCa prognostic assessment. 
Thus, GS is fundamental in predicting PCa natural history and the risk of 
recurrence after radical prostatectomy (RP) or radiotherapy, influencing treatment 
approach [30].  
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Notwithstanding, inter-observer variability remains the principal pitfall of 
GS, although the updated system has proved to increase in 20% agreement 
between observers [32, 33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Modified Gleason grading system for PCa. 
Pattern 1: Closely-packed, uniform, rounded to oval glands; 
Pattern 2: More loosely arranged glands with smooth ends that minimally invade non neoplastic tissue; 
Pattern 3: Irregular size and shape glands with more infiltrative margins; 
Pattern 4: Fused, cribriform or ill-defined glands; 
Pattern 5: Almost no glandular differentiation. Adapted from [34]. 
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1.3.5 Clinical and Pathological Staging  
PCa is an important cause of cancer morbidity and mortality worldwide and 
therefore, accurate staging is a crucial approach for prognosis assessment and 
treatment planning [35].  
The most commonly used staging system for PCa was proposed by the 
American Joint Committee on Cancer (AJCC) and the Union for International 
Cancer Control (UICC): the TNM (Tumor Node Metastasis) system [36]. This 
staging system consists in the evaluation of primary tumor (T) extension, 
regional involved lymph nodes (N) and presence or absence of distant metastases 
(M) (Table 1) [37]. According with AJCC and UICC, TNM stage for PCa could be 
clinical (cTNM) or pathological (pTNM) [38].  
Clinical stage provides information regarding cancer extension, before 
definitive treatment onset and is generally achieved by DRE, TRUS or magnetic 
resonance imaging (MRI), and serum PSA levels [36, 39].  
Since pathological staging requires macro and microscopic evaluation of 
surgical specimen and dissected regional lymph nodes, it can only be determined 
after RP [4, 38, 40]. Consensually, pathological staging predicts recurrence with 
more accuracy than clinical stage and, it is also useful as a prognostic factor [40]. 
In this sense, clinicians developed monograms, combining independent 
prognostic factors such as capsule invasion, preoperative serum PSA levels, GS 
for the RP specimen, positive surgical margins, lymph node metastases, seminal 
vesicles involvement and distant metastases [4, 35, 41]. 
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Table 1: The 2010 AJCC/UICC TNM staging classification for PCa. Adapted from [36].  
PRIMARY TUMOR (T) 
CLINICAL 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent tumor neither palpable nor visible by imaging  
T1a Tumor incidental histologic finding in 5% or less of tumor resected 
T1b Tumor incidental histologic finding in more than 5% of tumor resected  
T1c Tumor identified by needle biopsy 
T2 Tumor confined within prostate gland 
T2a Tumor involves one half of one side or less 
T2b Tumor involves more than one half of one lobe but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through prostate capsule 
T3a Extracapsular extension (unilateral or bilateral)  
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal 
vesicles, such as: external sphincter, rectum, bladder, levator muscles, 
and/or pelvic wall 
PATHOLOGIC (PT)* 
pT2 Organ confined 
pT2a Unilateral, one half of one side or less 
pT2b Unilateral, involving more than one half of one lobe but not both lobes 
pT2c Bilateral disease 
pT3 Extraprostatic extension 
pT3a Extraprostatic extension or microscopic invasion of bladder neck 
pT3b Seminal vesicle invasion 
pT4 Invasion of rectum, levator muscles and/or pelvic wall 
REGIONAL LYMPH NODES (N) 
CLINICAL 
Nx Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
PATHOLOGIC (PN) 
pNx Regional nodes not sampled 
pN0 No positive regional nodes 
pN1 Metastasis in regional node(s) 
DISTANT METASTASIS (M) 
M0 No distant metastasis  
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
*There is no pathologic pT1 classification 
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1.3.6 Prostate Cancer Therapies 
Unequivocally, PCa is associated with a substantial mortality and 
morbidity, but in fact, most men do die with, rather than of, their PCa. 
Furthermore, given the intrinsic heterogeneity of PCa, men with similar history 
(clinical stage, serum PSA levels and biopsy features) can have significantly 
different outcomes. Hereupon, the main challenge to physicians is to recognize 
the faction of men with aggressive local PCa and thus choose a suitable therapy 
approach for these, sparing the remainder of the morbidity associated to 
overtreatment [4]. Current therapeutic options for PCa include surgery, radiation, 
hormone therapy and chemotherapy. Treatment choice usually depends on 
disease and patient ´s features such as age, life expectancy, life quality, TNM 
stage, GS and preoperative serum PSA level [37]. 
Concerning clinically localized PCa, standard treatment options are active 
surveillance (AS), RP, external-beam radiotherapy and interstitial radiation therapy 
(brachytherapy).  
AS is suitable for patients with very-low risk of PCa progression. The 
requirements for belong to this group of patients are: T1-T2 TNM staging (organ 
confined PCa), GS ≤6 and serum PSA level < 10ng/mL. These patients are 
subjected to frequent PSA measurements and prostatic biopsies to detect disease 
progression [31].  
RP remains the standard procedure for high-risk locally advanced PCa, 
showing survival benefits comparing with conservative methodologies. Patients 
with a biopsy GS ≤8, TNM staging ≤ T3a, PSA level < 20ng/mL and life expectancy 
of 10 or more years are indicated for this surgery. This procedure consists in the 
removal of whole prostate gland and seminal vesicles and has been optimized in 
order to decrease the associated morbidities, such as erectile dysfunction and 
urinary incontinence [31, 42].  
Other therapeutic option for organ-confined PCa is radiotherapy since both 
external-beam radiotherapy and brachytherapy present rates of disease-free 
survival similar to that obtained by RP. External-beam radiotherapy is a non-
invasive methodology with low morbidity rates suitable for patients without 
disseminated disease and which not tolerate RP or brachytherapy [42]. Regarding 
brachytherapy, this approach consists in the permanent ultrasound guided 
insertion of radioactive seeds, with the half-life of 60 days, directly in the 
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prostate. This methodology has fewer side effects when compared to RP and 
external-beam radiotherapy, being recommended for patients with low-volume 
and low-grade PCa and [42, 43]. A combination of these two modalities of 
radiotherapy improves survival outcome and is used in patients harboring 
intermediate to high-risk PCa [4]. 
Considering high risk PCa, hormone therapy (i.e. androgen deprivation 
therapy [ADT]) is the widely accepted therapeutic strategy. Once prostate is a 
hormone-responsive gland and about 80-90% of PCa are sensitive to AR action at 
the time of diagnosis, hormone therapy aims to avoid androgen effect either by 
suppressing its secretion or inhibiting its action [42, 44].  
Generally, ADT consists in administration of Gonadotropin-releasing 
hormone analogs (GnRH), also called luteinizing hormone releasing-hormone 
(LHRH), concomitantly with anti-androgens (i.e. flutamide and bicalutamide), 
causing a significant reduction of prostatic secretory cells by apoptosis [3, 45, 
46]. Additionally, ADT can also be used as neoadjuvant or adjuvant therapy, in 
combination with surgical or radiation therapy [47].  
Even if ADT has a palliative intent and, indeed, leads to 70-80% symptoms 
reduction, within 18 to 24 months from treatment initiation most tumors acquire 
a hormone refractory phenotype, also known as castration-resistant disease. [48-
50].  
Regarding castration-resistant PCa (CRPC), this stage of PCa is often 
connected with biochemical progression (increased levels of serum PSA), as well 
as by metastatic progression [51]. In order to understand the progression to 
CPRC, two models have been proposed: the adaptation model and clonal 
selection model (Figure 6) [51, 52].  
 
The adaptation model supports that androgen-dependent PCa cells 
experience genetic and epigenetic events that allow themselves adapt to 
androgen-depleted environment, culminating in ADT resistance that consequently 
leads to cancer relapse. The mechanisms that confer resistance to ADT include 
increase of androgen levels in tumor, amplification of AR gene, gain-of-fuction 
mutations, alternative-splice variants of AR, changes in expression of co-
regulatory molecules, androgen independent activation of AR signaling and other 
bypass pathways that enables cancer development, under the pressure of 
androgen-deprivation conditions [51].  
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Conversely, clonal selection model proposes that subclones of PCa cells 
with different degrees of androgen dependence are already present in tumor 
before onset of ADT and the selective pressure of low-androgen conditions leads 
to the outgrowth of the pre-existing castration-resistant clones [51].  
In this last stage of PCa, the morbidity and mortality rates are significantly 
higher and chemotherapy (docetaxel combined with either prednisone or 
estramustine, the first-line treatment in metastatic CRPC) is one of the few 
available options, exhibiting a limited efficiency (response rate about 10-20%) and 
short survival (only 2 months) [48-50, 53]. Mitoxantrone combined with 
prednisone is the second-line approved treatment for metastatic CRPC, being 
capable to improve patients’ life quality (reduction of pain), however it does not 
show a survival benefit [54, 55]. 
Indeed, considering that metastatic CRPC is incurable, the available 
treatments only aim to improve patients’ life quality. 
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Figure 6: Models of progression to CRPC. Adapted from [52]. 
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2 EPIGENETICS 
2.1 Deciphering its Growing Relevance 
The paradigmatic question about what exactly we are and how we evolve 
over the years is no more answered that we are only the reflection of the genetic 
code that composes our DNA. In a precise and accurate manner we can find this 
answer in Lehninger´s classic textbook: we are our proteins. In fact, proteins are 
the final point of the central dogma of molecular biology, since they are 
generated from our DNA and this process is intermediated by RNA molecules. 
However, not all RNA molecules encode proteins, although these non-coding 
molecules have crucial cellular functions. So we are not just our genes, they are 
solely part of the history and this is where epigenetics takes its role [56]. 
Etymologically, “Epigenetics” derives from the Greek epi - which means 
beyond – genetics. Conrad Waddington firstly used this term to define “the casual 
interactions between genes and their products, which bring the phenotype into 
being” [57]. Actually, epigenetic defines heritable and transient changes in gene 
expression that are not due to any alterations in the DNA sequence [58]. This 
emerging field provides the scientific basis to explain differences between two 
monozygotic twins, on two cloned animals artificially generated from the same 
DNA donor, the expression of only one X chromosome in female or simply the 
fact that just paternal or maternal traits are expressed in offspring [56, 59-61]. 
The three major epigenetics mechanisms are: DNA methylation, histone 
post-translation modifications and non-coding RNAs. This highly sophisticated 
machinery is crucial to regulate chromatin structure and transcriptional activity 
[62]. Epigenetics marks are primarily established during embryonic development 
and play a crucial role throughout differentiation, being maintained across during 
cellular replication and division [62, 63].  
Despite being an area in expansion, epigenetic show a promisor 
evolutional capacity as Esteller clearly described: “Genetics has had several jump-
starts since the late recognition of Mendel’s work, the elucidation of the double-
strand DNA structure by Watson, Crick, Wilkins, and Franklin, and the completion 
of the human genome projects led by Francis Collins and Craig Venter. In 
epigenetics, we are still trying to catch up. What lies ahead could be even more 
exciting.” [56]. 
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2.2 Epigenetic Mechanisms of Gene Expression Control 
2.2.1 DNA Methylation 
Among the three epigenetic mechanisms of gene expression control 
previously mentioned, DNA methylation is, so far, the most studied [64]. Briefly, 
DNA methylation consists in the addition of a methyl group at the 5’ position of a 
cytosine ring inside CpG dinucleotides being this enzymatic reaction carried out 
by DNA methyltransferases [65]. CpG dinucleotides are distributed in an 
organized manner throughout the genome, with condensing of these 
dinucleotides at 5’-gene regulatory region, recognized as CpG islands [66]. 
Interestingly, a great portion of human gene promoters present a CpG island, 
which are frequently unmethylated in normal cells and become specifically 
methylated during development and tissue differentiation [64]. 
Regarding transcriptional impact, DNA methylation is associated with 
chromatin repressive states and consequently with inhibition of gene expression 
[64]. This repressive effect of DNA methylation can be exerted by directly 
avoiding RNA polymerase and transcription factors binding [65, 67] or indirectly, 
through the recruitment of methyl-CpG-binding domain (MBD) proteins which in 
turn recruits histone-modifying and chromatin-remodeling complexes [64]. 
DNA methylation patterns are found altered in disease processes, 
especially in cancer [68]. Generally tumors show a global decrease in DNA 
methylation levels, specifically in repetitive DNA sequences, coding regions and 
introns, leading to a progressive malignant phenotype through events such as 
chromosomal instability, reactivation of transposable elements and loss of 
imprinting [57]. Simultaneously and with the same carcinogenic contribute, also 
occurs hypermethylation at specific CpG islands, mainly in promoter regions of 
tumor-suppressor genes [57, 64, 69] (Figure 7). 
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2.2.2 Non-coding RNAs 
In the last decade, attention has been focused in non-coding RNAs 
(ncRNAs). In fact, only 2% of human genome codifies proteins and about 90% is 
transcribed into RNA molecules [70, 71]. Although these molecules do not 
encode proteins, they are very important in specific cellular pathways such as 
splicing, chromosome dynamics, RNA editing, inhibition of translation, mRNA 
destruction, X-chromosome silencing in females and DNA imprinting [72, 73]. 
Depending on interactions and activity, ncRNAs are divided in: small nucleolar 
RNAs (snoRNAs), PIWI-interacting RNAs (piRNAs), transcribed ultraconserved 
regions (T-UCRs), large intergenic non-coding RNAs (lincRNAs), long non-coding 
RNAs (lncRNAs) and the spotlight within the group, microRNAs (miRNAs) [74].  
MicroRNAs (miRNAs), the most studied class of ncRNAs, repress the mRNA 
translation either by degradation or inhibition of mRNA, depending on the 
accuracy of matching miRNA-mRNA [75, 76]. Even so, although several studies 
describe miRNAs as repressors of transcription, recent data have indicated that 
they could also act as positive regulators of transcription [77]. This small size 
class of ncRNAs composes only about 1% of human genome, however it’s 
Figure 7: Altered DNA-methylation patterns in carcinogenesis. The hypermethylation of CpG 
islands of TSGs is a common alteration in cancer cells leading to the transcriptional 
inactivation of these genes and the loss of their normal cellular functions. In cancer cells, is 
observed a global hypomethylation, especially at repetitive sequences. Adapted from [69]. 
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estimated that they regulate the expression of 50% of human genes [78]. 
Additionally, one miRNA can target many mRNAs, which in turn can be targeted 
by several miRNAs [75]. Thereby, due the scope of miRNA regulation, they play 
important functions in biological processes such as apoptosis, differentiation and 
proliferation [78, 79].  
MiRNAs aberrant expression has been widely reported in several diseases, 
especially in cancer. The disruption of normal miRNA expression patterns is 
associated with genetic and epigenetic events [71, 74, 80]. A trend to a global 
miRNAs downregulation is observed in cancer, although upregulation also has 
been described [81]. Concerning miRNA role in carcinogenesis, depending on the 
neoplastic context and target genes, miRNAs can act as oncogenes (oncomiRs) or 
tumor-suppressors [82]. Hereupon, tumor-suppressors miRNAs decreased 
expression in cancer can be attributed to deficiencies in miRNA biogenesis 
leading to anomalous expression of their targets. In turn, oncomiRs 
overexpression and/or amplification promote a decreased expression of their 
miRNA-target tumor-suppressor genes, which could contribute to tumor induction 
[82].   
 
2.2.3 Histone Post-Translational Modifications 
In eukaryotic cells, chromatin is the macromolecular complex formed by 
DNA and histone proteins that contains the inherited material of cells [83]. The 
basic functional unit of chromatin, nucleosomes, contain 147 base pairs of DNA 
wrapped around a histone octamer, which is composed by one pair of histones 
H2A, H2B, H3 and H4, linked by H1  (Figure 8) [83-85]. A great portion of histone 
covalent post-translational modifications (PTMs) is established in histone tails 
[86]. PTMs define the chemical modifications of proteins that signal to other 
proteins, which in turn recognize the modification [87]. Additionally, chromatin is 
a dynamic structure that is divided in two major regions: heterochromatin, which 
is recognized as highly condensed regions that contain inactive genes; and 
euchromatin, which is relatively open and comprise transcriptional active genes 
[83].  There are several PTMs described so far such as methylation, acetylation, 
phosphorylation, ubiquitylation, sumoylation and deamination.  
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The epigenetic machinery responsible for the dynamics of PTMs can be 
divided into different groups based on their biological function: writers that lay 
down epigenetic marks in histones; readers which recognize them; and erasers 
that remove the PTMs (Figure 9) [88]. The distinct patterns of PTMs within the 
histone tails have been recognized as “histone code” and along with DNA 
methylation play a major role in gene activity regulation [83, 89] 
 Regarding methylation and acetylation, the respective epigenetic writers 
comprise histone methyltransferases (HMTs) and histone acetyltransferases 
(HATs), while epigenetic erasers are composed by histone demethylases (HDMs) 
and histone deacetylases (HDACs) [88].  
Histone acetylation has an important impact in gene transcriptional activity 
since it affects the electrostatic charge of the histones. Alterations in electrostatic 
charge of the histones influence not only the chromatin structure but also the 
binding affinity of histones to DNA. Indeed, the chromatin packaging controls the 
capacity of epigenetic readers to recognize histone PTMs in histone tails and 
thus, active or repress transcription [88, 90, 91]. 
 
 
Figure 8: Chromatin structure and histone PTMs. (a) Chromatin is made of repeating units of 
nucleosomes, composed by ≈ 147 base pairs of DNA wrapped around a histone octamer consisting 
in two copies each of the core histones H2A, H2B, H3 and H4. Linker H1 is positioned on top of the 
nucleosome core. (b) Histone PTMs on histone tails (N-terminal). Adapted from [85]. 
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Since histone PTMs are crucial for gene transcription regulation, they 
require a balance between the epigenetic machinery responsible by their 
dynamics. Disruption of this balanced is associated with pathological processes 
including cancer [92]. However, the plasticity nature of PTMs allowed the 
developing of “epigenetic drugs”, capable to target abnormal activity/expression 
of important chromatin-modifying enzymes [93, 94]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Epigenetic writers, readers and erasers. Adapted from [88]. 
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3 HISTONE METHYLATION AND PROSTATE CANCER 
3.1 Histone Methylation: Basics of an Extensive Field 
Unlike acetylation, histone methylation does not alter the charge of the 
target residue, whereby is unlikely to be able to directly change chromatin 
structure. Methylation marks serves as binding sites for proteins that maintain 
nucleosomes together or signalizes for additional regulatory proteins such as 
binding domains [87]. Histone methylation occurs mainly in lysine residues (K), 
by lysine methyltransferases (KMTs), and in arginine residues (R) by arginine 
methyltransferases (PRMTs). Lysines can be mono- (me1), di- (me2) or tri-
methylated (me3), whereas arginines might be mono- and symmetrically (me2s) 
or asymmetrically di-methylated (me2a) [93]. 
 Transcriptional effect of histone methylation is relatively more complex 
than histone acetylation. Histone methylation can either lead to transcription 
repression or gene activation depending on the specific target residue, as well as 
the degree of methylation (Figure 10) [95]. 
Figure 10: Major lysine methylation marks on the amino-termini of histones H3 and H4. The 
embedded numbers refer to the methylated amino acid residue on each histone. The general 
function of each mono- , di- and trimethylation state is depicted in dots of distinct colors, according 
with its function. Adapted from [95]. 
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In actively transcribed genes, there is an enrichment of H3K4me2 and 
H3K4me3, H3K36me3 and H3K79. Conversely, H3K9me3, H3K27me3 and 
H4K20me3 are associated with repressed genes [96]. More than 50 HMTs have 
been described, so far, and all of them use S-adenosylmethionine (SAM) as a co-
substrate to transfer methyl groups [87, 93]. Additionally, HMTs can be classified 
in three different groups: SET domain KMTs, non-SET domain KMTs and PRMTs 
[97]. Regarding PRMTs, they might be classified in three types: Type I, II and III 
generate monomethylarginine (MMA). Specifically, type I catalyzes the 
subsequent generation of asymmetric dimethylarginine (ADMA) and type II 
catalyzes symmetric dimethylarginine (SDMA) [98]. Histone methylation was 
considered for many years a stable and static histone modification until the 
discovery of the first KDM (Lysine-specific demethylase 1 - LSD1) in 2004 [93]. 
Since then, more than 30 HDMs were described and classified in two families: 
Lys-specific demethylases (LSD) and jumonji C (JMJC) histone demethylases [96]. 
This dynamic character of histone methylation requires an efficient balance 
between HMTs and HDMs in order to avoid alterations in normal cellular 
phenotype [92]. 
3.2 Histone Methylation: Relevance in Prostate Cancer 
Aberrant histone modification profiles as well as the deregulated activity of 
correspondent enzymes are linked to cancer onset and progression, mainly by 
two mechanisms: alterations on normal gene expression of both oncogenes and 
TSGs, and genomic instability [93] (Figure 11).  
Concerning PCa, several alterations of normal histone modifications 
patterns have been associated with different clinical outcomes. While H3K4me1 
and H3K4me2 are associated with increased risk of PCa recurrence [99, 100], 
methylation of H3K4 and H3K27 was correlated with tumor grade or recurrence 
[99, 101]. Additionally, levels of H4R3me2 and H3K4me2 allowed the distinction 
between two groups of low-grade PCa with different prognosis outcome (GS = 6 
or GS < 6) [102]. 
Similarly to aberrant patterns of histone modifications, abnormal 
expression of some histone modifying-enzymes was also reported in PCa. 
Deregulation of some KMTs, such as Mixed-Lineage Leukemia 2 (MLL2), Mixed-
Lineage Leukemia 3 (MLL3), nuclear receptor binding SET domain protein 1 
(NSD1), enhancer of zeste homolog 2 (EZH2) or SET and MYND domain containing 
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3 (SMYD3), were already described in PCa [99, 103]. EZH2 catalyzes repressive 
marks (H3K27me3 and at less extent H3K9me2) and was demonstrated to be a 
driver in prostatic carcinogenesis [102, 104-107]. EZH2 was found overexpressed 
in metastatic PCa being associated with intensification of tumoral phenotype 
[108, 109]. 
Moreover, repression of AR target genes was correlated with methylation 
of H3K9. Some studies showed that knockdown of its specific demethylases 
(LSD1, lysine-specific demethylase 3A – KDM3A; lysine-specific demethylase 4C – 
KDM4C) increased the levels of repressive marks on the regulatory regions of AR 
targeted genes, which in turn leads to their decreased expression [110, 111]. 
Additionally, LSD1 upregulation is associated with aggressive PCa, CRPC and high 
risk of disease relapse [112-114]. 
 
 
Therefore, a better understanding of the mechanisms underlying 
disruption of methylation marks in cancer is needed to develop new drugs and 
molecular strategies, capable to inhibit the imbalance between HMTs and HDMs, 
responsible for aberrant deposition of histone´s methylation marks. 
 
 
Figure 11: Histone-modifications map for a typical chromosome in normal and cancer cell. In 
normal cell, histone marks associated with active transcription are enriched in genomic regions 
including the promoters of tumor-suppressor genes, whereas DNA repeats and other 
heterochromatic regions are characterized by presence of repressive marks. In cancer cells, there 
are loss of the ‘active’ histone marks on tumor-suppressor gene promoters, and loss of repressive 
marks at subtelomeric DNA and other DNA repeats, leading to a more ‘relaxed’ chromatin 
conformation in these regions. Adapted from [69]. 
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1 BRIEF CONTEXTUALIZATION 
The work presented in this Master Thesis arises from a previous PhD 
project developed in Cancer Epigenetics and Biology Group (GBEC), which aimed 
to clarify the role of HMTs and HDMs in PCa. 
 Thereby, in order to identify what HMTs and HDMs displayed an abnormal 
expression pattern during prostatic carcinogenesis, TaqMan Array 96-Well Plates 
were designed to assess expression levels on 37 HMTs and 20 HDMs in normal 
prostate and PCa tissue samples by RT-qPCR.  
Five normal prostate tissues (NPTs) and ten PCa samples were selected to 
cover the full spectrum of prostate carcinomas considering the GS and 
pathological stage (relevant clinical and pathological data are depicted in Table 
2).  
The mRNA levels of the genes studied were normalized to the beta-
glucuronidase (GUSB) reference gene and the median value of NPTs and PCa 
samples was chosen to calculate the fold variation in gene expression between 
groups, using the comparative Ct method. 
 
 
Table 2: Clinical and pathological features of patients included in the screening of HMTs and 
HMDs expression in NPTs and PCa samples. 
 
 
CLINICOPATHOLOGICAL 
FEATURES 
PCA NPT 
NUMBER OF PATIENTS, N 10 5 
AGE (YEARS) 
 Median (range)  59 (53 – 71) 61 (49 – 66) 
PSA LEVELS (NG/ML)  
Median (range) 12.3 (3.5 – 19.9) NA 
PATHOLOGICAL STAGE, N (%)  
pT2 4 (40.0) 
NA pT3a 2 (20.0) 
pT3b 4 (40.0) 
GLEASON SCORE, N (%)  
< 7 3 (30.0) 
NA 
≥ 7 7 (70.0) 
NA, Not applicable  
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The result of this screening of HMTs and HDMs expression levels showed 
an overexpression of protein arginine methyltransferase 6 (PRMT6) in PCa 
samples comparing with NPTs samples (Figure 12). 
 
 
Figure 12: Expression levels of PRMT6 in NPT and Tumor. 
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1 AIMS  
PCa is one of the most incident cancers in men worldwide. Mortality rates 
are not decreasing and their prevalence shows a worrying rising trend to the next 
years. This malignancy is quite complex and heterogeneous, showing a clinical 
course that ranges from indolent tumors to highly aggressive and metastatic 
ones. Additionally, therapeutic options for early-stage PCa exhibit good outcomes 
but in advanced stages, treatment is far less effective. 
Therefore, the major clinical challenge is to identify PCa cases with highly 
specific and sensitive methods; and concomitantly, to discriminate men with 
aggressive disease to better adequate treatment option and avoid overtreatment 
and unnecessary morbidities in patients with clinically indolent tumors. 
Histone PTMs are thought to be involved in the control of gene expression 
either by influencing chromatin compaction and signaling to several protein 
complexes. Hence, an appropriate expression of the enzymatic machinery 
responsible for dynamic regulation of histone PTMs is required for appropriate 
gene expression. Furthermore, abnormal HMTs and HDMs expression patterns as 
well as the altered patterns of histone PTMs have been found associated with 
carcinogenesis. 
As previously mentioned, PRMT6 was found upregulated in PCa samples 
when compared to NPT samples. Additionally, this arginine methyltransferase 
was also found upregulated in other cancers, such as lung and bladder cancer 
[115].  
Hereupon, the main purpose of this Master Thesis was to further explore 
the importance of PRMT6 deregulation in prostate carcinogenesis. In order to 
achieve this objective, this project was comprised in the following set of tasks: 
I. Confirmation of the overexpression of PRMT6 in PCa, in an 
independent and relatively large series of prostatic tissue (NPT, HBP, 
PIN and PCa samples); 
II. To ascertain the correlation between PRMT6 expression with 
clinicopathological parameters;  
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III. Assess the expression of PRMT6, at protein level, in the same series of 
prostatic tissue used in the first task; 
IV. Evaluate the impact of PRMT6 knockdown in malignant phenotype of 
PCa cell lines; 
V. Verify the effect of PRMT6 knockdown in histone PTMs´ patterns; 
VI. Identify putative target genes and molecular pathways regulated by 
PRMT6; 
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1 CLINICAL SAMPLES: PATIENTS AND SAMPLE COLLECTION 
Samples of 195 primary tumors of prostate and 38 PIN lesions were 
prospectively collected from patients with clinically localized prostate 
adenocarcinoma, consecutively diagnosed and primarily treated with RP at the 
Portuguese Oncology Institute, Porto, Portugal. For control purposes, samples of 
15 non-neoplastic prostate tissues normal prostate tissue (NPT) were obtained 
from the peripheral zone of prostates not harboring PCa, collected from 
cystoprostatectomy specimens of bladder cancer patients. All tissue specimens 
were immediately frozen after surgery and storage at -80ºC, following informed 
consent. Five-micron thick frozen sections were cut and stained for the 
identification of the areas of PCa (i.e., the index or dominant tumor) and normal 
tissue. Then, the tissue block was trimmed to maximize the yield of target cells 
(>70% of target cells). Histological slides from formalin-fixed, paraffin embedded 
(FFPE) tissue fragments were also obtained from the same surgical specimens and 
assessed for GS and TNM stage. Relevant clinical data were collected from the 
clinical records, and these studies were approved by the institutional review 
board [Comissão de Ética para a Saúde-(CES 295/2013)] of Portuguese Oncology 
Institute - Porto, Portugal. 
 
2 RNA ISOLATION 
All tissue samples were suspended in TRIzol® reagent (Invitrogen, 
Carlsbad, CA, USA) and total RNA was purified using the PureLink™ _ RNA Mini Kit 
(Invitrogen) following manufacturer’s recommendations. The concentration, 
purity and integrity of RNA samples were determined on a Nanodrop ND-1000 
(ThermoScientific, Wilmington, DE, USA) and agarose gel electrophoresis and then 
RNA samples were stored ate -80ºC.  
 
3 PRMT6 GENE EXPRESSION IN CLINICAL SAMPLES 
PRMT6 mRNA levels were assessed in the previously described series of 
prostate tissue samples used in this study. Briefly, a total of 300ng was reverse 
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transcribed and amplified using TransPlex® Whole Transcriptome Amplification 
Kit (Sigma-Aldrich®, Schnelldorf, Germany) with subsequent purification using 
QIAquick PCR Purification Kit (QIAGEN, Germany), according to manufacturer’s 
instructions. Expression levels of PRMT6 and BGUS, a housekeeping gene used as 
endogenous control, were evaluated using TaqMan® Gene Expression Assay 
(Applied Biosystems®, Life TechnologiesTM, Foster City, CA, USA) 
(Hs_00250803_s1 and Hs_99999908_m1, respectively). To calculate the relative 
expression levels in each sample, the expression values of PRMT6 were 
normalized using the median of the reference gene (BGUS) to obtain a ratio 
(PRMT6/GUSB). Each plate included 2 negative controls and five sequential 
dilutions of a cDNA from human prostate RNA (Ambion®, Invitrogen, Carlsbad, 
CA, USA) to construct a standard curve for each plate. All experiments were run 
in triplicate. 
4 IMMUNOHISTOCHEMISTRY 
Histological slides from FFPE tissue fragments were achieved from the 
same surgical specimens used in clinical sample series through the realization of 
4μm thickness histological sections. Firstly, slides were deparaffinized in xylene 
(Sigma-Aldrich®, St. Louis, MO, USA) and then hydrated in a decreasing series of 
ethanol solutions (Merck, Darmstadt, Germany). Epitope retrieval was performed 
with ethylenediaminetetraacetic acid (EDTA) buffer (Thermo Scientific, Waltham, 
MA, USA) for 20 minutes, in a microwave at 700W. Endogenous peroxidase 
activity was neutralized for 20 minutes with 0.6% hydrogen peroxide (Merck). 
Protein detection was performed using the NovolinkTM Max Polymer Detection 
System (Leica Biosystems, Nussloch, Germany), according to manufacturer 
instructions. Slides were incubated overnight with a mouse monoclonal antibody 
specific for PRMT6 (sc-271744; Santa Cruz Biotechnology Inc., Santa Cruz, CA) in 
a 1:150 dilution at 4ºC, inside a humid chamber. Subsequent washing steps were 
performed with tris buffered saline with Tween® 20 (TBS-T) (Sigma-Aldrich®). 
Antigen-antibody binding reaction was revealed through the slides incubation for 
7 minutes, in the dark, in a 0.05% (m/v) 3,3’-diaminobenzidine (DAB) solution 
(Sigma-Aldrich®) in phosphate-buffered saline (PBS) (Biochrom Ltd., Cambridge, 
United Kingdom) previously activated with a 0,1% hydrogen peroxide solution. 
Counterstaining of the slides were obtained with hematoxylin (Merck) for about 5 
seconds and then slides were washed for 1 minute in a 0.25% ammonium 
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solution (Merck). Lastly, the slides were dehydrated in an increasing series of 
ethanol content and diaphanized in xylene. After the coverslip was mounted, 
slides were dried. For positive control of the immunohistochemistry (IHC) 
reaction, FFPE tissue from a normal testis was also included. 
Slides were observed at the optical microscope and evaluated for PRMT6 
immunoexpression by an experienced Uropathologist. Scoring criteria were 
adapted from a previous publication of our research group [116]: +1 for weak 
expression in ≤ 50% of cells; +2 for weak expression in > 50% of cells or 
moderate expression in ≤ 50% of cells; +3 for moderate expression in > 50% of 
cells or intense expression (which typically occurred in more than 50% of cells).  
5 CELL CULTURE 
In present study, although five PCa cell lines (LNCaP, 22RV1, VCaP, PC-3 
and DU145) were firstly screened for PRMT6 expression, only LNCaP and PC-3 
were maintained in culture for further in vitro studies. Concerning these two PCa 
cell lines, LNCaP is a hormone-sensitive and PC-3 is a hormone refractory cell line. 
Both LNCaP and PC-3 were kindly provided by Prof. Ragnhild A. Lothe from the 
Department of Cancer Prevention at The Institute for Cancer Research at Oslo, 
Norway. 
Cell lines were grown using the recommended medium and correspondent 
supplements (Table 3) and 1% of Penicillin-Streptomycin (P-S) (GIBCO, Invitrogen, 
Carlsbad, CA, USA), in an humidifying chamber (37ºC and 5% CO
2
). TrypLE™ 
Express (GIBCO) dissociation reagent allowed subculture the selected cell lines to 
harvest them. Additionally, the cultured cell lines were routinely tested by a 
specific multiplex PCR for contamination by Mycoplasma spp. 
 
 
Table 3: Culture media conditions for PCa cell lines 
PCA CELL LINE GROWTH MEDIUM SUPPLEMENTS 
PC-3 RPMI-1640 + F-12 10% Fetal bovine serum 
(FBS) 
LNCAP RPMI-1640 
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6 PRMT6 KNOCKDOWN IN SELECTED PCa CELL LINES 
PRMT6 knockdown was achieved through viral transduction in LNCaP and 
PC3 cell lines using MISSION® shRNA Lentiviral Transduction Particles 
(SHCLNV_TRCN0000299934 for LNCaP cell line and SHCLNV_TRCN0000299933 
for PC-3 cell line; Sigma-Aldrich®) in the presence of polybrene (Santa Cruz 
Biotechnology Inc.) as described by the manufacturer. Moreover, control LNCaP 
and PC3 cells were generated using a MISSION® Non-Mammalian shRNA Control 
Transduction Particles (SHC002V; Sigma-Aldrich®). After transduction, stable 
clones with shRNA were selected with Puromycin dihydrochloride (cat. 631306, 
Clontech Laboratories Inc.) at a final concentration of 3μg/mL or 5μg/mL in 
LNCaP or PC3 cells, respectively.  
7 RNA EXTRATION FROM SILENCED CELL LINES 
Cell culture flasks (75 cm3) at 100% confluence with LNCaP and PC-3 PRMT6 
silenced cells were harvested with a dissociation reagent, TrypLE™ Express 
(GIBCO®) and centrifuged for 5 minutes at 1,200 rpm. Cell pellets were 
ressuspended in 1 mL of PBS (GIBCO®), and centrifuged for 5 minutes at 1,200 
rpm. The supernatant was discarded and cell pellets were stored at -80oC. 
Total RNA from LNCaP and PC-3 PRMT6 silenced cells was extracted by 
TRIzol® Reagent (Invitrogen), according to manufacturer instructions. The pellets 
generated from total RNA extraction were dried and eluted in RNA storage 
solution (1 mM sodium citrate, pH 6.4) (Ambion®, Life TechnologiesTM, Foster 
City, CA, USA). The concentration, purity and integrity of RNA samples were 
determined as previously described and RNA samples were stored ate -80ºC. 
8 CDNA SYNTHESIS 
In order to evaluate PRMT6 mRNA expression in LNCaP and PC-3 PRMT6 
silenced cells, 1000ng of cDNA was synthesized from total extracted RNA. A 
cDNA synthesis was performed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems®) according manufacturer instructions. 
Reverse transcription was performed in a Veriti® Thermal Cycler (Applied 
Biosystems®) and samples were then stored at -20ºC.	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9 PRMT6 EXPRESSION ASSAY 
In order to confirm the efficiency of PRMT6 knockdown in transduced cell 
lines, PRMT6 mRNA levels were assessed by RT-qPCR. Briefly, cDNA products 
were diluted 10x in distilled water and reactions were carried out in 96-well 
plates using a 7500 Real-Time PCR system (Applied Biosystems®). For each well, 
9 μL of cDNA product were mixed with 10 μL TaqMan® Universal PCR Master Mix 
(Applied Biosystems®) and 1 μL TaqMan® Gene Expression Assay, specific for 
PRMT6 (Hs_00250803_s1, Applied Biosystems®). Each sample was run in 
biological and experimental triplicate, and in every plate, two negative template 
controls were included. 
The analysis method used to ascertain PRMT6 knockdown in selected PCa 
cell lines was ΔΔCt method. LNCaP and PC-3 cells transduced with MISSION® Non-
Mammalian shRNA Control Transduction Particles (Sigma-Aldrich®), from now on 
designated as LNCaP and PC-3 Sh-Scramble, respectively, were used to normalize 
results for LNCaP and PC-3 cells treated with MISSION® shRNA Lentiviral 
Transduction Particles specific for PRMT6, from now on designated LNCaP and 
PC-3 Sh-PRMT6. BGUS was used as a reference gene to normalize results obtained 
for the PRMT6 gene. 
10 PROTEIN EXTRACTION AND QUANTIFICATION 
Protein was extracted from whole-cell lysates using the Kinexus Lysis 
Buffer with Lysis Buffer Cocktail (Kinexus Bioinformatics Corporation, Vancouver, 
British Columbia, Canada). Briefly, growth medium was removed from 75 cm3 cell-
culture flasks, and cells were washed with PBS to remove the residual culture 
medium. After PBS removal, 200 µL of Kinexus Lysis Buffer with Lysis Buffer 
Cocktail were added to each flask. Cells were scrapped with the help of a cell 
scrapper (Santa Cruz Biotechnology Inc.) to stimulate cell detachment and lysis, 
being then collected to a 1.5 mL tube. Cell lysate was sonicated in ice for 4 x 10 
seconds cycles, with 10 seconds gap between each cycle. After that, tubes 
containing cell lysates were centrifuged for 30 minutes at maximum speed at 
4ºC. Supernatant was carefully transferred to a new 1.5 mL tube.  
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Protein concentration was determined using BCA assay (Thermo Scientific, 
Waltham, MA, USA) according to manufacturer's information and extracted 
protein samples were stored at -80ºC. 
11 WESTERN BLOT ANALYSIS 
PRMT6 gene silencing and alterations in the different protein levels were 
assessed by Western Blot analysis. Briefly, 30 µg of total protein was heated for 5 
minutes at 95ºC to promote protein denaturation, centrifuged and finally loaded 
in a 10% sodium dodecyl sulfate polyacrylamide gel, for further electrophoresis 
(SDS-PAGE). Proteins were blotted onto 0.2 µm nitrocellulose or PVDF membranes 
(Bio-Rad Laboratories Inc., Hercules, CA, USA) and after their blocking membranes 
were incubated overnight at 4ºC with primary antibody (detailed information 
about primary antibodies in Table 4). The blots were developed with the ClarityTM 
Western ECL Substrate (Bio-Rad Laboratories Inc.) and AmershamTM Hyperfilm ECL 
(GETM Healthcare, Buckinghamshire, United Kingdom), to which membranes were 
exposed. 
To ascertain equal loading of protein, the membranes were stripped with 
Antibody Erasing Buffer (Komabiotech, Seoul, South Korea) and reprobed with a 
monoclonal mouse antibody against β-Actin (1:8000, Sigma-Aldrich®) or with a 
rabbit polyclonal antibody against Histone H3 (1:500, Abcam).  
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Table 4: Essential information about the primary antibodies used in this study. 
PRIMARY 
ANTIBODY 
DILUTION HOST COMPANY 
ANTI-PRMT6 1:500 Rabbit pAb 
Novus Biologicals 
(Littleton, CO, USA) 
ANTI-
H3R2ME2A 
1:500 Rabbit pAb Novus Biologicals 
ANTI-H3K4ME3 1:500 Rabbit pAb Abcam 
ANTI-AKT 1:500 Mouse mAb Santa Cruz Biotechnologies Inc. 
ANTI-PAKT 1:500 Mouse mAb 
Millipore 
(Billerica, MA, USA) 
ANTI-MTOR 1:1000 Rabbit mAb 
Cell Signaling Technology 
(Cell Signaling Technology, Inc., Danvers, 
MA, USA) 
ANTI-P21 1:500 Mouse mAb 
BD Biosciences 
(Franklin Lakes, NJ, USA) 
ANTI-P27 1:500 Mouse mAb 
Transduction Laboratories 
(BD Biosciences, Franklin Lakes, NJ, USA) 
ANTI-AR 1:250 Rabbit pAb Cell Signalling 
ANTI-PSA 1:6000 Rabbit mAb Abcam 
pAb: Polyclonal antibody; mAb: monoclonal antibody 
12 CELL VIABILITY ASSAY 
The effect of PRMT6 on LNCaP and PC-3 cell lines viability was assessed by 
3-(4, 5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium (MTT; Sigma-Aldrich®) 
assay. This assay consists on the cleavage of yellow-colored, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide, into a blue-colored 
formazan by the mitochondrial enzyme succinate-dehydrogenase. Briefly, the 
cells were seeded in 96-well plates (Sarstedt, Numbrecht, Germany) at different 
concentrations (Table 5), depending on cell line, in 200μL of complete medium 
and incubated in a humidified chamber at 37ºC and 5% CO
2
. The viability assay 
was performed after cells adhered to the plate (0 hours) and in subsequent days 
(24h, 48h and 72h). On each viability assay, cells were incubated with a solution 
of MTT (Sigma-Aldrich®) diluted in complete medium at 37ºC for 2h. Then, MTT 
solution was removed, formazan crystals were dissolved in Dimethyl sulfoxide 
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DMSO (Sigma-Aldrich®) and plates were shaken for 15 minutes for complete 
dissolution.   
An automated plate reader (FLUOstar Omega, BMG Labtech, Offenburg, 
Germany) at 540nm with a reference filter of 630nm allowed for colorimetric 
quantification. The optical density (OD) was directly proportional to the number 
of viable cells. Three biological independent experiments were performed with 
methodological triplicates for each experiment. 
 
Table 5: Number of cells plated for in vitro experiments in PCa cell lines used in this study. 
CELL LINE 
NUMBER OF CELLS PER WELL 
(96-WELL PLATES) 
PC-3 4000 
LNCAP 8000 
 
13 APOPTOSIS ASSAY 
Apoptotic levels were assessed using the APOPercentage™ kit (Biocolor 
Ltd., Newtownabbey, Northern Ireland, UK). Shortly, this assay consists in 
APOPercentage dye incorporation by cells undergoing apoptosis through 
phosphatidylserine transmembrane movements. 
 Cells were grown in 96-well plates (Sarstedt) at different concentrations 
depending on cell line (Table 5), in complete medium and incubated in a 
humidified chamber at 37ºC and 5% CO
2
. 72h after cell adherence to the 96-well 
plate, the APOPercentage assay was performed according to manufacturer's 
instructions. Quantification of apoptosis was performed using a FLUOstar Omega 
microplate reader (BMG Labtech), by the OD measurement of the released dye at 
550nm with a reference filter of 620 nm. To normalize the OD measured in the 
apoptotic test to the cell number, the OD of apoptosis assay was divided by the 
OD of the viability assay, also performed in 96-well plates. The results of the 
apoptosis assay on the silenced cells were expressed as the ratio of the values 
obtained for scramble cells (set as 100%). Three biological independent 
experiments were performed with methodological triplicates for each experiment. 
 
Materials and Methods 
 
 
45 
14 MIGRATION ASSAY 
The impact of PRMT6 silencing in migration ability of PC-3 cell line into a 
defect in a monolayer culture was determined using the wound-healing assay. 
Briefly, cells were grown (37ºC and 5% CO
2
 atmosphere) to full confluence in 24-
well plates, the medium was removed and scratches were performed using a 
100µL tip. Cells were then washed with PBS and medium replaced. Scratch 
closure was analyzed under the inverted microscope and images were captured at 
different time points. Three biological independent experiments were performed 
with methodological quadruplicates for each experiment. 
15 INVASION ASSAY 
Invasion capacity of PC-3 PRMT6 silenced cells was evaluated through 
Biocoat Matrigel Invasion Chambers (BD Biosciences) according to manufacturer’s 
protocol (Figure 13). Briefly, 2.5x104 cells in 500µL of serum-free medium were 
seeded in Matrigel inserts. Additionally, for each well plated with Matrigel inserts, 
the lower portion of insert was completed with 500µL of medium with serum as a 
chemoattractant. Then, plates were incubated in a humidified chamber at 37ºC 
and 5% CO
2
 for 24h. Non-invading cells were removed from the top of the insert 
and cells that migrated were fixed in methanol and stained with VECTASHIELD® 
Mounting Media containing DAPI (Vector Laboratories, Inc., Burlingame, CA, USA). 
Migrated cells were manually counted under a fluorescence microscope and 
results were displayed as percentages of invasion relative to scramble. Three 
biological independent experiments were performed with methodological 
duplicates for each experiment. 
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16 STATISTICAL ANALYSIS 
In order to ascertain statistical significance for comparisons made in this 
work, non-parametric test were used. Kruskal-Wallis test was used for 
comparisons between more than two non-related groups, and Mann-Whitney U 
test was used to compare two non-related groups. These tests were used both in 
clinical samples and in vitro studies. A receiver operator characteristic (ROC) 
curve was used to assess the performance of PRMT6 as diagnostic biomarker. A 
Spearman Correlation was used to test an association between transcript levels of 
different genes. Wilcoxon Signed Rank test, another non-parametric test, was 
used to compare related samples from the same individual in study. Fisher’s 
Exact Test was used to measure the association between prostate tissues and 
immunoexpression. P-values were considered statistically significant when 
inferior to 0.05. When comparing multiple groups, Bonferroni’s correction was 
applied in subsequent paired comparisons, dividing the P-value by the number of 
comparisons performed (0.017, in the case of the present study). Statistical 
analyses were performed using SPSS software, version 22.0 (IBM-SPSS Inc., 
Chicago, IL, USA). Graphs were built using GraphPad Prism 6.0 software 
(GraphPad Software Inc., La Jolla, CA, USA).   
Figure 13: Principle of BioCoat Matrigel Invasion Chamber 
and subsequent analysis of invasion assay. (Adapted from 
www.bmglabtech.com) 
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1 PRMT6 GENE EXPRESSION IN A LARGE SERIES OF CLINICAL 
SAMPLES 
RT-qPCR assessment of PRMT6 mRNA levels was performed in a large 
series of 248 tissue samples (NPT=15; PIN=38; PCa=195). Figure 14 illustrates 
the overexpression of PRMT6 found in PIN lesions and in PCa samples compared 
to NPTs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 ASSOCIATION BETWEEN PRMT6 EXPRESSION LEVELS AND 
CLINICOPATHOLOGICAL FEATURES 
Relevant clinical and pathological characteristics of patients included in 
this study are depicted in Table 6. 
Briefly, NPT, PIN and PCa groups did not significantly differ in age 
distribution. Additionally, no statistically significant association was found 
between PRMT6 expression levels and clinicopathological parameters, such as 
serum PSA level, GS or pathological stage (pTNM). 
 
 
Figure 14: PRMT6 relative expression in prostate tissues. There is 
overexpression in PIN and PCa compared to NPTs. ****p<0.0001 
(Mann-Whitney U-test). 
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 Table 6: Clinical and pathological data of patients included in this study 
3 EVALUATION OF PRMT6 EXPRESSION AS DIAGNOSTIC 
BIOMARKER 
Given the PRMT6 expression patterns observed in our series, we assessed 
the potential performance of this enzyme as diagnostic biomarker for PCa. ROC 
curve analysis was performed for that purpose, enabling the definition of the best 
sensitivity and specificity values for an empirical cut-off expression level of 
0.265. PRMT6 performance as diagnostic biomarker for PCa is depicted in Figure 
15 and Table 7. 
 
 
 
 
 
 
 
  
 NPT PIN PCA 
NUMBER OF CASES, N 15 38 195 
AGE (YEARS) 
 Median (range)  64 (45-80) 65 (51-76) 64 (49-75) 
PSA LEVELS (NG/ML)  
Median (range) N.A. N.A. 8.24 (0-23) 
PATHOLOGICAL STAGE, N (%)  
pT2 
N.A. N.A. 
109 (56%) 
pT3a 67 (34%) 
pT3b 19 (10%) 
GLEASON SCORE, N (%)  
< 7 
N.A. N.A. 
66 (34%) 
= 7 115 (59%) 
≥ 7 14 (7%) 
N.A., Not applicable  
Figure 15: Performance of PRMT6 mRNA expression as a biomarker for PCa. 
ROC curve evaluating the ability of PRMT6 expression levels in discriminating 
PCa from normal prostate tissues. (AUC, area under curve; CI, confidence 
interval). 
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Table 7: Description of PRMT6 performance as diagnostic biomarker of prostate malignancy 
 
4 PRMT6 EXPRESSION OF MATCHED PIN AND PCa SAMPLES 
All the PIN lesions used in this study were matched with a primary PCa 
sample, deriving from the same patient. A Wilcoxon Signed Rank test was then 
performed to assess differences in PRMT6 expression levels between matched 
PIN and PCa. As depicted in Figure 16, expression levels were significantly higher 
in PIN lesions, compared to the respective PCa (p < 0.001).  
  
BIOMARKER CHARACTERISTIC VALUE 
SENSITIVITY (%) 70.3 % 
SPECIFICITY (%) 93.0 % 
POSITIVE PREDICTIVE VALUE (PPV) (%) 99.3 % 
NEGATIVE PREDICTIVE VALUE (NPV) (%) 93.0 % 
ACCURACY (%) 71.9 % 
 
Figure 16: Relative expression of PRMT6 in paired PIN and 
PCa tissue samples. 
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5 PRMT6 PROTEIN LEVELS IN A LARGE SERIES OF CLINICAL 
SAMPLES 
To assess PRMT6 protein expression in tissue samples, IHC was performed 
in a series of 248 FFPE prostate tissue samples (NPT=15; PIN=38; PCa=195) that 
perfectly matched with series of frozen tissues utilized for assessment of PRMT6 
mRNA expression. Table 8 depicts the distribution of IHC scores in each group of 
samples and illustrative examples are presented in Figure 17. 
 
Table 8: Immunohistochemical expression of PRMT6 in a series of NPT, PIN lesions and primary PCa. 
CLINICAL SAMPLE 
GROUP 
SCORE +1 
N (%) 
SCORE +2 
N (%) 
SCORE +3 
N (%) 
NPT 15 (100%) - - 
PIN 14 (37%) 15 (39%) 9 (24%) 
PCA 100 (51%) 63 (32%) 32 (16%) 
 
A significant increase of PRMT6 protein levels from NPTs to PIN lesions and 
PCa samples is apparent. Score distribution of PRMT6 immunostaining across the 
three groups of clinical samples is illustrated in Figure 18 - A. Paralleling PRMT6 
mRNA expression results, the highest percentage of cases scored as +2 and +3 
were found in PIN. 
A statistically significant association between PRMT6 transcript and 
protein levels was apparent (p < 0.001), indicating that, globally, PRMT6 protein 
levels follow the same trend as that of the transcript (Figure 18 – B). In pairwise 
comparisons, statistical significance was detected between scores +1 vs +2 and 
+1 vs +3 (p < 0.01 and p < 0.001, respectively). Additionally, a significant 
association was obtained between immunoexpression and prostate tissues. 
  
Table 9: Association between PRMT6 expression and prostate tissue. 
CLINICAL SAMPLE 
GROUP 
NORMAL 
EXPRESSION 
OVEREXPRESSION P 
NPT 15 (100%) - 
**** NEOPLASTIC PROSTATE 
TISSUE 
114 (49%) 119 (51%) 
Neoplastic Prostate Tissue: PIN lesions and PCa samples; Normal Expression: +1; Overexpression: 
+2 and +3; ****p<0.0001 (Fisher´s Exact Test). 
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Figure 17: Illustrative images of PRMT6 immunostaining in NPT, PIN and PCa samples. 
Figure 18: Distribution of PRMT6 immunoexpression (A) and of PRMT6 transcript levels (B) in a series of prostate 
tissue samples (NPT, PIN and PCa), grouped according to PRMT6 immunostaining. **p<0.01;***p<0.001;n.s. non 
significant (Mann-Whitney U-test). 
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6 KNOCKDOWN OF PRMT6 IN PC-3 AND LNCaP CELL LINES 
Firstly, PRMT6 expression levels were assessed by RT-qPCR in five PCa cell 
lines (LNCaP, 22RV1, VCaP, PC-3 and DU145) (Figure 19-A). All cell lines 
expressed PRMT6, although at variable levels. Then, the androgen responsive and 
the androgen refractory cell lines that expressed higher levels of PRMT6 (LNCaP 
and PC-3, respectively) were chosen for in vitro studies. Furthermore, effective 
PRMT6 knockdown was achieved in the selected cell lines and confirmed both at 
mRNA and protein level (Figure 19-B). 
A 
Figure 19: (A) PRMT6 expression in PCa cell lines. (B) The efficiency of PRMT6 
knockdown was confirmed at mRNA, using RT-qPCR (upper panel), and protein 
level, using Western-Blot (lower panel), in LNCaP and PC-3 cells. *p<0.05 (Mann-
Whitney U-test). 
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7 IMPACT ON VIABILITY AND APOPTOSIS OF PRMT6 
KNOCKDOWN IN PC-3 AND LNCaP CELL LINES  
In LNCaP PRMT6-knocked down cell line, the MTT assay showed a 33% and 
31% increase in cell viability at 24h and 48h, respectively. However, at 72h cell 
viability was similar to that of Sh-scramble (Figure 20-A). Concerning PC-3, a 
significant decrease in cell viability was observed after PRMT6 knockdown, both 
at 48h and 72h (10% and 24%, respectively) (Figure 20-B). Moreover, knockdown 
of PRMT6 led to an increase of apoptosis, in both LNCaP and PC-3 cell lines. 
Nevertheless, this increase was only statistically significant in PC-3 cells (Figure 
20-C and D). 
 
Figure 20: Impact of PRMT6 knockdown in cell viability and apoptosis of LNCaP and PC-3 cell lines. 
(A) Cell viability in LNCaP and (B) cell viability in PC-3: quantification of cell viability by MTT assay 
in Sh-Scramble and Sh-PRMT6 at 0h, 24h, 48h and 72h. Quantification of apoptosis by 
APOPercentage in Sh-Scramble, Sh-PRMT6 LNCaP (C) and PC-3 (D) at 72h. *p<0.05 (Mann-Whitney 
U-test). 
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8 EFFECT OF PRMT6 KNOCKDOWN IN MIGRATION AND 
INVASION CAPACITY OF PC-3 CELLS 
Because PC-3 is widely recognized as a highly invasive PCa cell line, we 
evaluated the impact of PRMT6 knockdown in migration and invasion potential in 
this cell line. A significant decrease in migration ability was observed in PC-3 
PRMT6-silenced cells (Figure 21-A). Furthermore, a decrease in invasion capacity 
of PC-3 PRMT6-silenced cells was also observed, although it did not reach 
statistical significance (Figure 21-B). 
Figure 21: Impact of PRMT6 knockdown in migration and invasion properties of PC-3. (A) Wound-
healing scratch assay in PC-3 cell line. The upper panel shows the migration rate at 12h and 16h, and 
the lower panel displays the illustrative images at the beginning and endpoint of the assay. (B) Matrigel 
Invasion assay in PC-3. The upper panel shows the percentage of invasive cells at 24h and the lower 
panel displays illustrative images at endpoint of the assay (24h). ***p<0.001 (Mann-Whitney U-test). 
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9 EFFECT OF PRMT6 KNOCKDOWN IN HISTONE PTMs 
PATTERNS IN PC-3 CELL LINE 
As PRMT6 knockdown produced phenotypic alterations in silenced PC-3 
cells, we ascertained alterations in histone marks established by this arginine 
methyltransferase. Therefore, western blot was performed to quantitate 
H3R2me2a. The observed reduction of this mark, established by PRMT6 [117], is 
illustrated in Figure 22. 
 
PRMT6 methyltransferase activity in arginine 2 of histone 3 counteracts the 
MLL complex activity on lysine 4 of the same histone, being mutually exclusive 
[117-119]. As PRMT6 was overexpressed in PCa samples, we evaluated the impact 
of this deregulation in MLL complex expression and activity. We had previously 
found that MLL family genes (MLL1-5) were downregulated in PCa [120]. Because 
the case series used in the present study is partially common to that of our 
previous publication, we interrogated the combined datasets concerning a 
putative association between PRMT6 and MLL complex expression. Although 
Spearman correlation analysis did not disclose an association between PRMT6 
and MLL complex transcript levels in primary PCa tissues, PRMT6 knockdown was 
associated with MLL3-5 upregulation in PC-3 cells (Figure 23). The same trend 
was observed for SMYD3, another H3K4me3 methyltransferase (Figure 23). 
H3R2me2a 
H3 
Figure 22: Reduction of asymmetrical dimethylation of 
arginine 2 of histone 3 after PRMT6 knockdown in PC-3 
cell line. 
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Moreover, the impact of PRMT6 knockdown on MLL complex activity in 
vitro was tested through the evaluation of the differences in H3K4me3 
expression, in PC-3 cells. However, no significant alterations in expression were 
apparent after PRMT6 knockdown (Figure 24 – A). 
Because PRMT6 activity is associated with a subset of transcriptionally 
inactive Hox genes and presumably also with some MYC-dependent genes [117], 
we evaluated MYC transcript levels before and after PRMT6 silencing. RT-qPCR 
analysis depicted a significant increase in MYC mRNA levels in PC-3 Sh-PRMT6 
(Figure 24 - B). 
 
Figure 23: Relative expression of methyltransferases that catalyze H3K4me3 in PC3 PRMT6-silenced cells. 
(A-E) MLL complex genes are upregulated in PC3 Sh-PRMT6 cells, reaching statistical significance for MLL3-
5. (F) SMYD3 is also significantly upregulated in PC3 knocked down cells. *p<0.05 (Mann-Whitney U-test).  
Figure 24: H3K4me3 and MYC expression after PRMT6 knockdown in PC-3 cell line. (A) Western blot 
analysis of H3K4me3 expression after PRMT6 knockdown in PC-3 cells. (B) MYC transcript levels in PC-
3 PRMT6 silenced cells. *p<0.05 (Mann-Whitney U-test).  
H3K4me3 
H3 
A 
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10 MOLECULAR PATHWAYS AND PUTATIVE TARGET GENES 
REGULATED BY PRMT6 
To find genes regulated by PRMT6, we evaluated putative targets 
associated with cellular processes and pathways relevant in PCa. Firstly, cellular 
senescence was investigated, since this biological process has been previously 
associated with PRMT6 activity [121, 122].  
Among molecules responsible for induction of cellular senescence, p21 
and p27 play a major role [121-123]. In PC-3 Sh-PRMT6 cells, western blot 
analysis showed a considerable increase of p27 expression whilst p21 was only 
slightly increased (Figure 25). 
 
Considering the decrease in invasion and migration ability of PC-3 Sh-
PRMT6 cells, we further evaluated the expression levels of genes involved in 
those cellular processes. We found that PRMT6 silencing was associated with 
matrix metalloproteinase 9 (MMP-9) downregulation and CD44 upregulation 
(Figure 26). 
Figure 26: Impact of PRMT6 knockdown in MMP-9 and CD44 transcript levels in PC-3 cell line. 
*p<0,05 (Mann-Whitney U-test). 
Figure 25: Western blot analysis of p21 and 
p27 expression in PC-3 cell line after PRMT6 
knockdown.  
p27 
p21 
β-Actin 
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The PI3K/AKT/mTOR pathway, which is frequently deregulated in PCa was 
also investigated [124].  In PC-3 Sh-PRMT6 cells, AKT, phosphorylated AKT and 
mTOR protein expression was significantly decreased (Figure 27), suggesting 
PI3K/AKT/mTOR pathway downregulation due to PRMT6 silencing. 
 
Finally, the AR pathway, which is critically involved in PCa initiation and 
progression [125], was examined. In PC-3 cells, which have only residual 
expression of AR [126], PRMT6 knockdown led to AR upregulation, both at 
transcript and protein level (Figure 28). To confirm these results, expression of 
PSA (a well-known downstream target of AR) was assessed, and an impressive 
increase in PSA protein levels was apparent in PC-3 Sh-PRMT6 cells (Figure 28 - B). 
 
 
 
 
 
 
 
 
 
Figure 23: Overexpression of AR in PC-3 PRMT6 silenced cells. RT-qPCR analysis of AR transcript 
levels in PC-3 cell line (left panel). Western blot analysis of AR and PSA protein levels in PC-3 cell 
line. *p<0,05 (Mann-Whitney U-test). 
PSA 
AR 
β-Actin 
 
B 
mTOR 
AKT 
Figure 27: Western blot analysis of AKT, 
pAKT and mTOR expression in PC-3 cell line. 
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1 DISCUSSION 
PCa is one of the most prevalent human malignancies, constituting a 
leading cause of morbidity and mortality. Over the last decades, PCa 
epidemiology has changed significantly. The widespread use of serum PSA 
testing as a PCa biomarker resulted in an anticipation of the median age of 
diagnosis and downstaging. Indeed, from a cancer mostly diagnosed in men over 
70 years-old and with clinically advanced disease, many PCa cases are now 
diagnosed in asymptomatic men aged 50 to 70 years, mainly with clinically 
localized disease and, therefore, with a greater chance of cure. However, the 
downside of this trend has been the increasing awareness of overdiagnosis and 
subsequent overtreatment due to the fact that serum PSA testing is unable to 
identify life-threatening PCa. Because currently used clinical and pathological 
tools do not accurately distinguish clinically indolent from aggressive tumors, a 
better understanding of prostatic carcinogenesis is required to improve diagnosis 
and management of this malignancy.  
Deregulation of epigenetic mechanisms has been increasingly recognized 
as a key player in tumorigenesis [57]. However, only more recently the critical 
role of altered patterns of histone post-translational modifications and of histone-
modifying enzymes activity has been emphasized [92]. Those alterations have 
been reported in several common cancers, including those of the prostate [92, 
93]. Histone methylation has received particular attention since alterations in 
expression of HMTs and HDMs, as well as corresponding histone modification 
patterns, seems to provide useful biomarkers for diagnosis and prognostication 
[99-102]. Recently, our research team has shown that several HMTs and HDMs 
were consistently deregulated in PCa and might be of prognostic significance 
[120]. In that study, PRMT6 was found overexpressed in PCa tissues, eventually 
discriminating normal from tumorous prostate tissues [120]. Herein, we extended 
those preliminary finding to a larger series of PCa cases and attempted to unravel 
the biological impact of PRMT6 deregulation in PCa cells. 
The PRMT6 argine methyltransferase, encoded by PRMT6 gene mapped at 
1p13.3, is preferentially localized in the nucleus [127]. This member of type I 
arginine methyltransferases family displays a high affinity for R2 of H3 [117, 
118]. Only PRMT6 has been proved to catalyze H3R2 asymmetric di-methylation, 
although PRMT4 has been documented to exert the same function, but only in 
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vitro [117]. Because H3R2me2 is a repressive mark, PRMT6 activity has strongly 
associated with transcriptional silencing [117]. Besides PCa, PRMT6 
overexpression of this enzyme has been reported in bladder and lung cancer [98, 
115]. The precise functions of PRMT6 are not completely understood at present, 
although it has been associated with altered cell proliferation, cellular 
senescence, DNA repair and innate immunity [121-123, 128, 129].  
Following our previous observation of PRMT6 overexpression in PCa [120], 
we validated this finding in a an extended series of cases, incorporating also PIN 
lesions, a putative PCa precursor. We confirmed that PRMT6 is frequently 
overexpressed in PCa and also in PIN lesions, compared to normal prostate 
tissues. Unexpectadly, PIN lesions displayed significantly higher PRMT6 transcript 
levels than PCa, a finding that was also apparent when only matched PCa and PIN 
lesions were analyzed. Theoretically, owing to the precursor role of PIN, 
intermediate levels of PRMT6 expression would be expected. The most likely 
explanation is that PRMT6 oncogenic role is more relevant during the earliest 
phases of tumorigenesis, although it remains important during cancer 
progression. This hypothesis is further supported by the lack of association 
between PRMT6 transcript levels and clinicopathological parameters of aggressive 
disease. Concerning the matched analysis, it should be recalled that a direct 
relation between paired PIN and PCa cases can not be inferred as a biological 
connection was not investigated in this series. 
Importantly, the variations of PRMT6 mRNA expression were confirmed at 
protein level, using IHC. Indeed, not only marked differences in IHC score were 
depicted between NPT, on the one hand, and PIN and PCa, on the other, but also 
the proportion of cases with +3 IHC score was higher in PIN. Interestingly, IHC 
scores globally correlated with PRMT6 transcript levels, although no significant 
differences were depicted between scores +2 and +3. This observation is 
probably due to the semi-quantitative nature of IHC scoring, which compressed 
PRMT6 expression variations into three categories, whereas the quantitation of 
mRNA expression levels is more discriminative. Indeed, using a cutoff value 
derived from ROC curve analysis to maximize performance, PRMT6 transcript 
levels were shown to accurately discriminate PCa from non-cancerous prostate 
tissues, confirming our previous findings [120] and suggesting a relevant role for 
PRMT6 mRNA expression as a PCa biomarker. Contrarily, PRMT6 
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immunoexpression is not likely to provide relevant information for PCa diagnosis 
as 51% of PCa samples display the same score as normal prostate tissues (+1). 
 
To ascertain the biological role of PRMT6 in PCa, we assessed the 
phenotypic effect of PRMT6 knockdown in LNCaP and PC-3 cell lines, which were 
chosen because it displayed the highest expression levels among, respectively, 
the androgen-sensitive and androgen-insensitive PCa cell lines tested. After 
achieving stable reduction of PRMT6 expression, cell viability, apoptosis, 
migration and invasion assays were carried out. Whereas an attenuation of the 
malignant phenotype (decrease of cell viability and increase of apoptosis) was 
consistently observed in PRMT6-silenced PC-3 cells, no permanent effect was 
apparent in PRMT6-silenced LNCaP cells. Following an initial increase in cell 
viability, no differences were depicted at 72h. This paradoxical behavior of LNCaP 
cells might be related with the AR regulating role of PRMT6. As PRMT6 activity 
leads to downregulation of AR, its silencing is likely to cause de-repression of AR 
transcription, with a positive impact in neoplastic cell viability. Thus, PC-3 was 
chosen for additional functional assays, testing migration and invasion capacities, 
which confirmed the effects of PRMT6 silencing in the attenuation of the 
malignant phenotype. 
Owing to the specificity of PRMT6 to asymmetrically dimethylate H3R2 
[117, 118], we hypothesized that PRMT6 knockdown could lead to a reduction of 
global levels of that methylation mark. Thus, the observed reduction in 
H3R2me2a is most likely due to the specificity of PRMT6 to catalyze that mark. 
PRMT6 activity counteracts that of the MLL complex and, thus, we also evaluated 
MLL complex expression and activity after PRMT6 knockdown. As expected, an 
increase in MLL complex was observed, but no significant difference in H3K4me3 
(the histone mark catalyzed by MLL) levels was apparent, even with concurrent 
SMYD3 (another methyltransferase that catalyzes H3K4me3) increased 
expression. Because several other enzymes (which we did not assess) catalyze the 
H3K4me3 mark, it is plausible to assume that variations in MLL and SMYD3 might 
not impact in H3K4me3 global levels. However, a gene-specific effect of those 
variations cannot be dismissed.  
To better understand the biological role of PRMT6 in PCa at molecular 
levels, we selected key genes involved in cellular pathways deregulated during 
prostate carcinogenesis. Owing to the reported involvement of PRMT6 in cellular 
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senescence [122, 123, 130], p21 and p27 expression levels were assessed in Sh-
scramble and Sh-PRMT6 PC-3 cells. Although both proteins were increased in Sh-
PRMT6 PC-3 cells, p27 showed the most impressive variation and these results 
are in line with those observed in other tumor models [122, 123, 130], implying 
that, indeed, PRMT6 overexpression in PCa is likely to interfere with normal 
cellular senescence, facilitating neoplastic transformation. Remarkably, p27 
seems to play an important role in prostate carcinogenesis as its expression 
decreases with increased tumor grade and stage [131-133] and p27 
downregulation has been associated with poor prognosis [131-134]. Furthermore, 
a decrease in cell proliferation accompanied by an increase in cell death due to 
apoptosis upon induction of p27 expression has been reported in PC-3 cell line 
[130], a finding that corroborates our results of phenotypic assays in Sh-PRMT6 
PC-3 cells. 
To further validate the results of the phenotypic assays, the expression of 
two molecules involved in tumor cell migration and invasion – MMP-9 and CD44 – 
was evaluated. In Sh-PRMT6 PC-3 cells, MMP-9 was found to be downregulated, 
whereas CD44 was upregulated. MMP-9 belongs to the group of gelatinases [135] 
and its role in promoting cancer invasion and metastasis is well documented in 
several cancer types [136-138]. Regarding CD44, a transmembrane glycoprotein 
involved in cell-cell and cell-matrix adhesion as well as in cell signaling, its role in 
cell migration, signaling and tumor metastasis is also well documented [139-
141]. In PCa, decreased expression of CD44 has been reported in primary 
tumors, with a pronounced lack of expression in metastasis [142, 143]. 
Moreover, CD44 downregulation has been associated with increased grade and 
pathological stage in PCa, predicting tumor recurrence and biochemical failure 
[144-146]. Thus, the observed variations in MMP-9 and CD44 expression in 
association with PRMT6 expression are in line with the reported role and altered 
expression of these molecules in primary PCa. Interestingly, CD44 decreased 
expression in PCa has been associated with aberrant promoter methylation [147]. 
Considering our results, we might speculate whether H3R2me2a catalyzed by 
PRMT6 might be an additional mechanism for CD44 silencing in PCa. 
Because alterations in the PI3K/AKT/mTOR pathway have been reported in 
42% of primary PCa and in 100% of metastatic tumors [148], key genes of this 
pathway have been also investigated. In line with the predicted effect of PRMT6 
silencing, downregulation of AKT, phosphor-AKT and mTOR were observed. 
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Although loss of expression of phosphatases and tensin homolog (PTEN), a 
negative regulator of PI3K/AKT/mTOR pathway, in PCa is a common explanation 
for the increased activity of that signaling pathway [149-151], PRMT6 activity 
might further provide conditions for PI3K/AKT/mTOR pathway activation. 
Importantly, both PTEN loss and AKT activation have been described to be 
associated with poor clinical outcome [152], biochemical recurrence after RP 
[153, 154], as well as resistance to radiation [155] and chemotherapy [156, 157].  
AR signaling is critical for the normal development, function and 
homeostasis of the prostate gland and its deregulation has been implicated in 
prostate carcinogenesis and tumor progression [158]. Although primary PCa is 
mostly an androgen-responsive tumor, the castration-resistant phenotype 
eventually emerges and is associated with clinical aggressiveness and 
refractoriness to ADT [158]. Several mechanisms have been implicated in the 
emergence of CRPC, including heterogeneous loss of AR expression, associated 
aberrant promoter methylation in 18% to 28% of cases [159, 160]. Additionally, 
the lack of AR expression has been associated with increased invasiveness [161, 
162]. PC-3 cells express AR at very low levels and might be, thus, considered a 
good model of CRPC. We found that PRMT6 silencing was associated with 
restored AR expression, which was functional, as demonstrated by increased PSA 
expression. Moreover, AR upregulation might also contribute to decreased 
migration and invasion capabilities documented in Sh-PRMT6 PC-3 cells. 
Interestingly, strategies that restore AR expression and, thus, overcome 
castration-resistance, might be of clinical utility [161, 162]. Hence, PRMT6 
downregulation and/or inhibition might provide an innovative therapeutic 
strategy for CRPC, through restoration of AR expression, re-sensitizing neoplastic 
cells to ADT. Further studies, combining PRMT6 downregulation and exposure to 
anti-androgens (e.g., bicalutamide) are mandatory to ascertain the clinical 
viability of this therapeutic approach. 
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1 CONCLUSION AND FUTURE PERSPECTIVES 
In this study we confirmed, in a large series of prostate tissue samples, 
that PRMT6 was overexpressed in PCa, at both transcript and protein level. 
Intriguingly, PIN lesions displayed significantly higher PRMT6 expression levels, 
compared to PCa. Furthermore, PRMT6 mRNA levels are able to discriminate 
cancerous from non-cancerous prostate tissues. 
In stable PRMT6 knockdown models, attenuation of the malignant 
phenotype was consistently demonstrated in PC-3 but not in LNCaP cells, 
probably due to its different AR expression status. At molecular level, PRMT6 
silencing was associated with decreased H3R2me2a levels and increased MLL 
complex and SMYD3 expression, although global H3K4me3 levels remained 
unchanged. Moreover, the expression of several key genes, involved in critical 
cellular pathways, was shown to be affected by PRMT6 downregulation, including 
p21, p27, MMP-9, CD44, AKT, phospho-AKT, mTOR and AR, globally supporting 
an oncogenic role for PRMT6.  
Finally, restoration of AR expression in Sh-PRMT6 PC-3 cells, might be of 
clinical relevance as it may re-sensitize androgen-insensitive neoplastic cells to 
ADT. 
 
The therapeutical potential of PRMT6 silencing/inhibition is probably the 
most exciting finding of this study and it is surely the one that more deserves 
further studies. Chromatin immunoprecipitation (ChIP) experiments are required 
to firmly establish a link between PRMT6 activity and AR expression (de-
)regulation. Furthermore, the androgen sensitivity of Sh-PRMT6 PC-3 cells must 
be proven by exposure to di-hydro-testosterone, as well as through combined 
treatment with bicalutamide, to demonstrate the re-acquisition of sensitivity to 
ADT. 
Although results observed for Sh-PRMT6 LNCaP cells seem discouraging, 
the hypothesis that the paradoxical effect of PRMT6 downregulation in cell 
viability is due to increased AR expression must be tested. As LNCaP cells might 
be considered representative of androgen-sensitive PCa, which are those that 
predominate at diagnosis, the effects of PRMT6 inhibition/downregulation must 
be carefully investigated, to ascertain whether the combined therapeutic strategy 
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previously hypothesized for CRPC (PRMT6 inhibition and bicalutamide) might 
constitute a potentially harmful therapy for androgen-sensitive PCa. 
Importantly, in case the combined therapy proves useful in in vitro models, 
our study provides evidence that PRMT6 expression, assessed by IHC (a 
commonly used technique in most Pathology labs) might serve as a predictive 
marker of response, through the identification of PCa cases overexpressing 
PRMT6, which are those that are most likely to respond. 
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